The Obesity Crisis and GLP-1 Medications Obesity is a major public health concern in the United States, affecting over 42% of the population
[3] Pasqualotto, E., Ferreira, R
Consider supplementation if levels are low, typically 18-27 mg daily with vitamin C for absorption
Effects of resmetirom on metabolic-dysfunction associated steatohepatitis in patients with weight loss and/or diabetes taking glucagon-like peptide-1 receptor agonists and other diabetes therapies: a secondary analysis of the MAESTRO-NASH trial
The combination of strong GLP-1 appetite suppression with meaningful GIP-mediated metabolic improvement creates a synergistic effect that exceeds what either receptor could produce alone, a principle similar to why peptide stacking sometimes outperforms individual compounds
New publication in eClinicalMedicine The Lancet Discovery Science